NASDAQ:CTMX - CytomX Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CytomX Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.26 +0.18 (+2.54 %) (As of 02/27/2020 05:45 AM ET) Add Compare Today's Range$7.07Now: $7.26▼$7.6550-Day Range$6.75MA: $7.43▼$8.1252-Week Range$5.10Now: $7.26▼$13.35Volume834,600 shsAverage Volume355,089 shsMarket Capitalization$329.82 millionP/E RatioN/ADividend YieldN/ABeta0.77 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX Previous Symbol CUSIPN/A CIK1501989 Webhttp://www.cytomx.com/ Phone650-515-3185Debt Debt-to-Equity Ratio0.31 Current Ratio4.40 Quick Ratio4.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$59.50 million Price / Sales5.54 Cash FlowN/A Price / Cash FlowN/A Book Value$2.91 per share Price / Book2.49Profitability EPS (Most Recent Fiscal Year)($2.03) Net Income$-84,600,000.00 Net Margins-163.18% Return on Equity-90.62% Return on Assets-23.58%Miscellaneous Employees137 Outstanding Shares45,430,000Market Cap$329.82 million Next Earnings Date2/27/2020 (Confirmed) OptionableOptionable Receive CTMX News and Ratings via Email Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CTMX Rates by TradingView CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics Inc (NASDAQ:CTMX) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.13. The biotechnology company had revenue of $10.71 million for the quarter, compared to the consensus estimate of $23.58 million. CytomX Therapeutics had a negative return on equity of 90.62% and a negative net margin of 163.18%. View CytomX Therapeutics' Earnings History. When is CytomX Therapeutics' next earnings date? CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for CytomX Therapeutics. What price target have analysts set for CTMX? 9 Wall Street analysts have issued 12-month price targets for CytomX Therapeutics' shares. Their forecasts range from $8.00 to $23.00. On average, they expect CytomX Therapeutics' share price to reach $16.63 in the next year. This suggests a possible upside of 129.0% from the stock's current price. View Analyst Price Targets for CytomX Therapeutics. What is the consensus analysts' recommendation for CytomX Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytomX Therapeutics. What are Wall Street analysts saying about CytomX Therapeutics stock? Here are some recent quotes from research analysts about CytomX Therapeutics stock: 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (8/15/2019) 2. Nomura analysts commented, "Progressing IO Probody CX-072—next steps 2H19: CX-072 (PD-L1) in combo with full dose ipi (3mg/kg) is well tolerated—plans for next phase of combo will be revealed in near future. We view undifferentiated pleomorphic sarcoma as offering potentially easier CX-072 combo differentiation vs ipi/PD- (L)1, where this combo has not been tolerated. Monotherapy next steps in 2H19, but based on single-arm expansion data, we still see oppy for monotherapy strategy (e.g., autoimmune disease pts/pts intolerant to PD-1). Solid tumor candidate Ph2 dose, indication: Ph2 registration-worthy? Recall, CTMX saw responses to CX- 2009 in solid-tumor pts including those who failed TROP2 from IMMU. CX- 2009 still in dose refinement, starting at 8mg/kg and using a modified toxicity probability interval (mTPI) design." (8/11/2019) 3. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Overweight rating and 12-month price target of $21/share. CytomX stock currently trades at an EV of ~$100M ($8.80/sh cash), and the shares are down about 27% YTD (vs. +8.5% for NBI), triggered by updates at its R&D day earlier this year. We believe that the company’s lead early-stage clinical assets, based on modified antibodies, are partially de-risked and are highly discounted at the current valuation. For CX-2009, we think that evolving clinical updates in the next 6-12 months should alleviate investor concerns about its safety profile and that risk of potential clinical setback is overstated." (5/13/2019) 4. HC Wainwright analysts commented, "We utilize a probability of approval of 70% for we employ a 10% discount rate, and a 29% effective tax rate, yielding a total value of $1.6B, or a price per share of $34, assuming 47.6M shares outstanding and roughly $329M in cash and equivalents as of end-4Q19." (4/3/2019) Has CytomX Therapeutics been receiving favorable news coverage? Media headlines about CTMX stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CytomX Therapeutics earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for CytomX Therapeutics. Are investors shorting CytomX Therapeutics? CytomX Therapeutics saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 1,310,000 shares, a decrease of 14.9% from the January 30th total of 1,540,000 shares. Based on an average daily trading volume, of 436,900 shares, the days-to-cover ratio is currently 3.0 days. Approximately 3.0% of the company's stock are sold short. View CytomX Therapeutics' Current Options Chain. Who are some of CytomX Therapeutics' key competitors? Some companies that are related to CytomX Therapeutics include Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Revance Therapeutics (RVNC), Zogenix (ZGNX), NextCure (NXTC), Odonate Therapeutics (ODT), Akebia Therapeutics (AKBA), Phibro Animal Health (PAHC), Rocket Pharmaceuticals (RCKT), Supernus Pharmaceuticals (SUPN), Dermira (DERM), Enanta Pharmaceuticals (ENTA), Athenex (ATNX), Portola Pharmaceuticals (PTLA) and Kiniksa Pharmaceuticals (KNSA). What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), Amicus Therapeutics (FOLD), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Portola Pharmaceuticals (PTLA) and Sorrento Therapeutics (SRNE). Who are CytomX Therapeutics' key executives? CytomX Therapeutics' management team includes the folowing people: Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)Mr. Debanjan Ray, Sr. VP & CFO (Age 41)Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63) Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (6.25%), Victory Capital Management Inc. (6.19%), Renaissance Technologies LLC (4.54%), State Street Corp (2.18%), FMR LLC (1.82%) and BVF Inc. IL (1.69%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Frederick W Gluck, Lloyd A Rowland, Rachel Humphrey and Sean A Mccarthy. View Institutional Ownership Trends for CytomX Therapeutics. Which institutional investors are selling CytomX Therapeutics stock? CTMX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, State Street Corp, Spark Investment Management LLC, Alliancebernstein L.P., Congress Park Capital LLC, FMR LLC, Bank of America Corp DE and UBS Group AG. View Insider Buying and Selling for CytomX Therapeutics. Which institutional investors are buying CytomX Therapeutics stock? CTMX stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Panagora Asset Management Inc., EcoR1 Capital LLC, Marshall Wace LLP, Man Group plc, Victory Capital Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for CytomX Therapeutics. How do I buy shares of CytomX Therapeutics? Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $7.26. How big of a company is CytomX Therapeutics? CytomX Therapeutics has a market capitalization of $329.82 million and generates $59.50 million in revenue each year. The biotechnology company earns $-84,600,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe.View Additional Information About CytomX Therapeutics. What is CytomX Therapeutics' official website? The official website for CytomX Therapeutics is http://www.cytomx.com/. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected] MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 315 (Vote Outperform)Underperform Votes: 246 (Vote Underperform)Total Votes: 561MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/27/2020 by MarketBeat.com StaffFeatured Article: Google Finance Portfolio
